AUG 11, 2020 1:29 PM PDT

FDA Approves New Opioid for Short-Term Use

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has announced the approval of Olinvyk (oliceridine), a new opioid that can help manage moderate to severe acute pain in adults. 

To test the drug, researchers enrolled 1,535 patients with moderate to severe acute pain in randomized, placebo-controlled, open-label trials. Administered to patients having undergone bunion or abdominal surgery, patients on the drug reported decreased pain when compared to those taking the placebo. 

Approved for both inpatient and outpatient procedures, the drug is only available for short-term usage. Meanwhile, its maximum approved dose is 27mg, and its target market is high-risk patients, such as the elderly, those who are obese, or have renal problems. 

Overall, the new drug has a similar safety profile to other opioids, and the FDA warns potential users and medical practitioners alike of its potential for abuse. Nevertheless, like other opioids, its most common side effects include nausea, vomiting, dizziness, headaches, and constipation. The FDA also notes that the drug should not be given to patients with significant respiratory depression and acute or severe bronchial asthma in an unmonitored setting without equipment for emergency resuscitation. 

“Addressing the opioid crisis remains a top priority for the FDA. We will continue to do everything we can to reduce the number of Americans who are addicted to opioids and cut the rate of new addiction through a number of cross-agency initiatives,” says Douglas Throckmorton M.D., deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research. 

“Importantly, the FDA will only approve new drug applications, including those for opioid medications, following a rigorous review to evaluate the risks and benefits and ultimate determination that the data support safety and effectiveness. Of note, this particular medication is only indicated for use in a controlled clinical setting, meaning under medical supervision and not for use in a take-home prescription.”

 

Sources: BioworldFDA

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 04, 2020
Drug Discovery & Development
Fecal Transplant Successfully Treats Alcoholism
SEP 04, 2020
Fecal Transplant Successfully Treats Alcoholism
Researchers from Virginia Commonwealth University have found that fecal transplants can reduce drinking behaviors in peo ...
SEP 17, 2020
Immunology
COVID Vaccine Works in Macaques - What about in Humans?
SEP 17, 2020
COVID Vaccine Works in Macaques - What about in Humans?
Pharmaceutical giant Pfizer, in partnership with BioNTech has reported that one of its lead vaccine candidates has shown ...
SEP 01, 2020
Drug Discovery & Development
First Novel Compounds to Inhibit Cancer-Linked Enzymes
SEP 01, 2020
First Novel Compounds to Inhibit Cancer-Linked Enzymes
Researchers from the University of Michigan Rogel Cancer Center have worked on creating a therapeutic-based compound tha ...
SEP 21, 2020
Drug Discovery & Development
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
SEP 21, 2020
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
The World Health Organization has endorsed a protocol to put African herbal medicines through clinical trials as possibl ...
SEP 20, 2020
Drug Discovery & Development
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
SEP 20, 2020
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
Almost a year into the beginnings of the COVID-19 pandemic and we still do not have a Food and Drug Administration (FDA) ...
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
Loading Comments...